Acta Neuropathologica:对路易体相关突触核蛋白病具有高灵敏度和特异性的超灵敏RT-QuIC分析

2020-07-21 MedSci原创 MedSci原创

帕金森氏病(PD),路易体痴呆(DLB)和多系统萎缩(MSA)在内的突触核病是神经退行性疾病,其特征在于细胞内有毒的α-突触核蛋白(α-Syn)聚集体。

临床上,突触核变病表现出高度可变的表现,对治疗的反应和进展速度。因此,这些疾病的预后也非常多变。路易体病(LBD)是最常见的突触核病,包括DLB和绝大多数PD患者,临床上可能表现为帕金森氏症或认知功能减退(或两者兼有),并且两种非典型帕金森氏症(包括进行性核上性麻痹(PSP))的症状重叠),MSA和皮质基底肌变性(CBD)和神经退行性痴呆,主要是阿尔茨海默氏病(AD)。而且,证明孤立的REM睡眠行为障碍(iRBD)和纯/孤立的自主神经衰竭(PAF)等临床情况通常是由突触核蛋白病引起的。针对突触核蛋白病的生物标志物的鉴定在临床实践中对于鉴别和早期诊断,预后评估以及疾病进展的监测将具有重要价值。

方法:利用一种新的基于病原蛋白种子体外扩增的方法,该方法是通过迫使天然单体转化为其错折叠的对应物而获得的。在一种称为实时Quaking诱导转化(RT-QuIC)的播种淀粉样蛋白测定(SAA)中,将源自患病患者CSF或其他生物体液或组织的病原性样本与其天然对应物一起培养。然后使用间歇摇动以促进种子和底物之间的相互作用,迫使单体转化为其病原体。反应过程由硫代黄素实时监测,硫代黄素是一种荧光染料,结合淀粉样原纤维的典型特征即交叉β结构后,其发射增强。整个研究分析了439例病人的CSF或其他生物体液或组织。

结果:RT-QuIC能够鉴定出Creutzfeldt–Jakob病(CJD)CSF的错折叠形式的pr病毒蛋白(PrP),其特异性为100%,敏感性为95–98%,因此已被纳入该病的诊断标准中。通过证明该检测方法还可以准确地区分LBD和其他与α-Syn不相关的帕金森氏症或痴呆症,最近的研究表明CSF RT-QuIC也可以成功应用于突触核蛋白病 ,尤其是那些与LB病理相关的疾病。

原文链接:

Rossi, M., Candelise, N., Baiardi, S. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathiesActa Neuropathol 140, 49–62 (2020). https://doi.org/10.1007/s00401-020-02160-8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
    2020-10-06 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
    2021-03-13 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
    2020-10-17 longerg
  7. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1786656, encodeId=916a1e86656cf, content=<a href='/topic/show?id=1c5d13e9171' target=_blank style='color:#2F92EE;'>#pathologic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13791, encryptionId=1c5d13e9171, topicName=pathologic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Nov 10 04:32:01 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786362, encodeId=2d9c1e86362d7, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 06 13:32:01 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849988, encodeId=4f06184998864, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 13 16:32:01 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986092, encodeId=57b119860920e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat May 08 02:32:01 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899407, encodeId=25fa189940e52, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Jul 28 04:32:01 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754939, encodeId=de821e549395c, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Sat Oct 17 13:32:01 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775941, encodeId=80821e7594190, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Mar 29 03:32:01 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478796, encodeId=14e014e879695, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Thu Jul 23 14:32:01 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803783, encodeId=1225803e8340, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200722/d323ca6b5f23412390c3a983ce919c3f/c5703d60ca704cfcaf3392aab2d36bc5.jpg, createdBy=bc311718295, createdName=清晰c8c453e7, createdTime=Wed Jul 22 00:13:37 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
    2020-07-22 清晰c8c453e7

    学习到了

    0

相关资讯

Nat Commun:揭示淋巴结中重要信号通路,以更好理解病理生理过程

SARS、MERS以及最近的新型冠状病毒2019-nCoV等病原体已成为全球性威胁。淋巴结(LN)通过为免疫细胞的生长提供庇护所并抵抗病原体,从而与传染病作斗争。但是,人们对LN的特定内部运作方式知之甚少。韩国基础科学研究所(IBS)的科学家们发现Hippo-YAP/TAZ信号通路在LN的形成和维持中起主要作用。该研究报告发表在《Nature Communications》杂志上。

Cancer Cell:另辟蹊径 寻找肥胖与癌症的全新关联

肥胖已经逐渐成为了吸烟以外的第二大癌症可预防原因,越来越多的研究表明肥胖不仅与癌症的发病率有关,还与癌症的疾病进展和最终结果有关。因此,了解脂肪组织如何与体内肿瘤细胞进行通信一直是癌症研究人员的目标。

Radiology:用MRI指标探前列腺癌前列腺外侵犯之病理之实!

本研究旨在评价前列腺癌病理证实前列腺外侵犯(EPE)相关的MRI征象,并提出病理学EPE MRI分级系统。

Acta Neuropathologica:进行性核上性麻痹中tau蛋白病理的分布模式

进行性核上性麻痹(PSP)是一种4R-tau病理病,属于额颞叶变性(FTLD-tau)疾病

广东登革热病例上升明显 珠三角地区人们注意了

广东省卫生健康委员会13日通报登革热疫情信息,截至6月12日,今年该省18个地市共报告240例登革热病例,较2018年同期(44例)相比上升明显,其中,境外感染输入病例231例,柬埔寨占到近七成。登革热主要通过白纹伊蚊(花斑蚊)叮咬传播,该病传播速度快,目前无特异性的治疗药物,少数病例可出现严重出血、休克甚至死亡。广东疾控专家评估认为,由于今年该省受“厄尔尼诺”影响,雨水偏多气温偏高,环境非常适合

Eur Urol:分子亚型和免疫浸润对肌层浸润性膀胱癌新辅助Pembrolizumab治疗的病理响应和结果影响

PURE-01研究(NCT02736266)评估了肌层浸润膀胱癌(MIBC)中根治性膀胱切除术(RC)前使用pembrolizumab的治疗情况。最近,有研究人员评估了pembrolizumab和RC